NKTR

Nektar Therapeutics (NASDAQ:NKTR) is a San Francisco-based biopharmaceutical company founded in 1990 and publicly traded since 1994. The company focuses on discovering and developing novel medicines for areas of significant unmet medical need, particularly in immunology and oncology. Originally known for its proprietary PEGylation technology platform that enhances drug properties, Nektar has evolved into a clinical-stage biotechnology company with a pipeline of investigational therapies targeting autoimmune diseases and cancer. The company has undergone significant strategic restructuring in recent years, narrowing its focus to core programs while extending its cash runway through facility sales and workforce reductions.